From Evan Harris <[email protected]>
Subject Listen to Dr. Joshua Rhodes – How Does California Rate on New Electricity Competition Scorecard?
Date December 16, 2021 8:14 PM
  Links have been removed from this email. Learn more in the FAQ.
  Links have been removed from this email. Learn more in the FAQ.
PRI Policy Alert

View this email in your browser ([link removed])
[link removed]
Dr. Joshua Rhodes – How Does California Rate on New Electricity Competition Scorecard?
PRI "Next Round" Podcast
Dr. Joshua Rhodes, research associate with the Webber Energy Group at the University of Texas, Austin, joins us to discuss the findings of a new national scorecard on electricity competition in the 50 states, and discusses why electricity competition is key to reducing costs, increasing reliability, and lowering emissions in California and across the country.

Listen here. . . ([link removed])
[link removed]

[link removed]

John Batchelor and Dr. Henry Miller Share Latest Omicron COVID News from the UK
The John Batchelor Show | Henry Miller, M.S., M.D.
December 14, 2021
Dr. Henry Miller joins the John Batchelor Show to talk about the latest news coming out of the United Kingdom, NHS reports on omicron, how the new variant compares to other variants of the COVID-19 virus, and what it means for Europe and the United States. Miller also talks about how transmissible omicron is, how effective vaccines and boosters could be, and it’s impact on lockdowns, mask mandates, and travel.

Listen here. . . ([link removed])

------------------------------------------------------------
The FDA is standing in the way of at-home COVID-19 tests
The Washington Examiner | Sally C. Pipes
December 13, 2021

Yet companies still wait months for a decision on their application. One at-home test maker told ProPublica it submitted its application in March of this year, provided more information to the agency in May, and then waited months before the FDA denied it in September.

Read more. . . ([link removed])
------------------------------------------------------------

Comprehensive Regulatory Reform From The Bottom Up: The Case Of 340B
Forbes.com | Wayne Winegarden
December 12, 2021

Simply because the sales volume of 340B drugs is experiencing extraordinary growth does not mean that the program is achieving its purpose, and there is mounting evidence it is not. By attempting to help vulnerable patient populations in such an overly complicated manner, the 340B program creates inefficiencies throughout the broader healthcare system.

Read more. . . ([link removed])

------------------------------------------------------------

COVID Vaccine Benevolence: An opportunity that US companies and the federal government should seize
PRI Right By the Bay | Roger Bate
December 16, 2021

Most important for fighting future pandemics, vaccine distribution is key to prevent weakening of the process that led to the rapid development of these vaccines in the first place. Health activists around the world, and especially in rich nations, want to undermine drug company patent protection in general and specifically for these vaccines.

Read more. . . ([link removed])

============================================================
** Twitter ([link removed])
** Facebook ([link removed])
** YouTube ([link removed])
** LinkedIn ([link removed])
** Website ([link removed])
Copyright © 2021 *Pacific Research Institute*, All rights reserved.
You are receiving this email because you opted in via our website.

Our mailing address is:
P.O. Box 60485 Pasadena, CA 91116

** ([link removed])

Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.
Screenshot of the email generated on import

Message Analysis